Gilead Presents New HIV Treatment And Cure Research Data
Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...
Gilead Sciences (NasdaqGS:GILD) Advances HIV Treatment With Promising Lenacapavir And Biktarvy Data
Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This ...
Clinical Trials Arena on MSN3d
MSD to push for approval of HIV combo after Phase III success
MSD’s HIV treatment is now back on track after an earlier hit which saw the FDA place a clinical hold on the therapy.
Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference ...
Nasdaq4d
Gilead Presents Encouraging Long-term Data For Biktarvy In People With HIV And HBV Coinfection
ALLIANCE is an ongoing Phase 3 study to evaluate Biktarvy versus dolutegravir plus emtricitabine/tenofovir disoproxil fumarate F/TDF, DTG+F/TDF, in adults with HIV-1/HBV co-infection initiating ...
pharmaphorum6d
GSK's Dovato matches rival Biktarvy with less weight gain
GSK has fired a shot across the bows of Gilead Sciences' HIV juggernaut Biktarvy, with new data showing its rival therapy Dovato is as effective but causes less weight gain. The results of the ...
Zacks Investment Research on MSN3d
Biotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & More
Mergers and acquisitions grabbed the spotlight in the biotech sector once again this week after Bristol Myers Squibb BMY ...
pharmaphorum9d
Switch study says patients prefer ViiV’s injectable HIV drug
When ViiV Healthcare and Johnson & Johnson launched their once-monthly injectable HIV treatment Cabenuva in 2021, they predicted that patients would prefer that option to the need to take tablets ...
The Motley Fool1mon
Gilead Sciences Beats Q4 EPS Forecast
The company views its leadership in treating and preventing HIV, with key products like Biktarvy and Descovy, as a fundamental strength. These products not only enhance its financial performance ...
Morningstar5d
Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option
Biktarvy Demonstrates High Rates of Viral Suppression in People with HIV/HBV Coinfection ALLIANCE (NCT03547908) is an ongoing Phase 3 study evaluating Biktarvy versus dolutegravir 50 mg (DTG ...